The stock's fall snapped a three-day winning streak.

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

Biotechnology is a rapidly evolving sector with significant advancements anticipated between 2025 and 2035. As innovations in ...

CFO Beth Jantzen reported total revenues of $1.2 million for Q1 2025, a year-over-year increase driven by higher product revenue from DNA Tagging and increased isotopic testing services. Operating ...

Healthy Environment and Endocrine Disruptor Strategies (HEEDS) now provides a comprehensive history of the endocrine disruptor scientific field via an online timeline. Complete with citations, it ...